Discontinuation symptoms in depression and anxiety disorders

International Journal of Neuropsychopharmacology

Volumn 10, Issue 1, 2007, Pages 73-84

  Baldwin, David S ^a,e   Montgomery, Stuart A ^b   Nil, Rico ^c   Lader, Malcolm ^d  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

^c H LUNDBECK A S   (Denmark)

^d KING'S COLLEGE LONDON   (United Kingdom)

^e ROYAL SOUTH HANTS HOSPITAL   (United Kingdom)

Author keywords

Affective disorders; Discontinuation effects; Escitalopram; Paroxetine; Venlafaxine

Indexed keywords

ANTIDEPRESSANT AGENT; ESCITALOPRAM; PAROXETINE; PLACEBO; VENLAFAXINE;

ADULT; AGITATION; AMNESIA; ANGER; ANXIETY; ANXIETY DISORDER; BURNING SENSATION; CHECKLIST; COMPARATIVE STUDY; CONFUSION; CONTROLLED STUDY; CRYING; DIZZINESS; DREAMING; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG SENSITIVITY; FATIGUE; FEMALE; GENERALIZED ANXIETY DISORDER; HEARING DISORDER; HUMAN; INCIDENCE; IRRITABILITY; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MOOD DISORDER; MUSCLE TONE; MYALGIA; NAUSEA; NERVOUSNESS; PANIC; PRIORITY JOURNAL; RESTLESSNESS; REVIEW; SIDE EFFECT; SLEEP DISORDER; SOCIAL PHOBIA; SOMNOLENCE; SWEATING; SYMPTOM; TREATMENT DURATION; TREMOR; UNSTEADINESS; WITHDRAWAL SYNDROME;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANXIETY DISORDERS; CITALOPRAM; CYCLOHEXANOLS; DEPRESSIVE DISORDER, MAJOR; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; PAROXETINE; SUBSTANCE WITHDRAWAL SYNDROME; TIME FACTORS; TREATMENT OUTCOME; WITHHOLDING TREATMENT;

EID: 33846301022     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145705006358     Document Type: Review

References (24)

1. Baldwin DS, Hindmarch I, Huusom AKT, Cooper J (2004a). Escitalopram and paroxetine in the short and long-term treatment of major depressive disorder (MDD). International Journal of Neuropsychopharmacology 7 (Suppl. 2), S168-S169.
2. Baldwin DS, Huusom AKT, Mæhlum E (2004b). Escitalopram and paroxetine compared to placebo in the treatment of generalised anxiety disorder (GAD). European Neuropsychopharmacology 14 (Suppl. 3), S311.
3. Bielski RJ, Ventura D, Chang C-C. (2004). A double-blind comparison of escitalopram and venlafaxine extended release in the treatment of major depressive disorder. Journal of Clinical Psychiatry 65, 1190-1196.
4. Black DW, Wesner R, Gabel J (1993). The abrupt discontinuation of fluvoxamine in patients with panic disorder. Journal of Clinical Psychiatry 54, 146-149.
5. Black K, Shea C, Dursun S, Kutcher S (2000). Selective serotonin reuptake inhibitor discontinuation syndrome: proposed diagnostic criteria. Journal of Psychiatry and Neuroscience 25, 255-261.
6. Fava M, Mulroy R, Alpert J, Nierenberg AA, Rosenbaum JF (1997). Emergence of adverse events following discontinuation of treatment with extended-release venlafaxine. American Journal of Psychiatry 154, 1760-1762.
7. Garner EM, Kelly MW, Thompson DF (1993). Tricyclic antidepressant withdrawal syndrome. Annals of Pharmacotherapy 27, 1068-1072.
8. Haddad PM (2001). Antidepressant discontinuation syndromes. Drug Safety 24, 183-197.
9. Hindmarch I, Kimber S, Cockle SM (2000). Abrupt and brief discontinuation of antidepressant treatment: effects on cognitive function and psychomotor performance. International Clinical Psychopharmacology 15, 305-318.
10. Judge R, Parry MG, Quail D, Jacobson JG (2002). Discontinuation symptoms: comparison of brief interruption in fluoxetine and paroxetine treatment. International Clinical Psychopharmacology 17, 217-225.
11. Lader M, Stender K, Bürger V, Nil R (2004). The efficacy and tolerability of escitalopram in 12- and 24-week treatment of social anxiety disorder: a randomised, double-blind, placebo-controlled, fixed-dose study. Depression and Anxiety 19, 241-248.
12. Liebowitz MR, Stein MB, Tancer M, Carpenter D, Oakes R, Pitts CD (2002). A randomised, double-blind, fixed-dose comparison of paroxetine and placebo in the treatment of generalized social anxiety disorder. Journal of Clinical Psychiatry 63, 66-74.
13. Linden M, Ludewig K, Munz T, Dierkes W (2003). Dosage finding and outcome of venlafaxine treatment in psychiatric outpatients and inpatients: results of a drug utilization observation study. Pharmacopsychiatry 36, 197-205.
14. Michelson D, Fava M, Amsterdam J, Apter J, Londborg P, Tamura R, Tepner RG (2000). Interruption of selective serotonin reuptake inhibitor treatment. British Journal of Psychiatry 176, 363-368.
15. Montgomery SA, Åsberg M (1979). A new depression scale designed to be sensitive to change. British Journal of Psychiatry 134, 382-389.
16. Montgomery SA, Dürr-Pal N, Loft H, Nil R (2003). Relapse prevention by escitalopram treatment of patients with social anxiety disorder (SAD). European Neuropsychopharmacology 13 (Suppl. 4), S364.
17. Montgomery SA, Huusom AKT, Bothmer J (2004a). A randomised study comparing escitalopram with venlafaxine XR in patients in primary care with major depressive disorder. Neuropsychobiology 50, 57-64.
18. Montgomery SA, Kennedy SH, Burrows GD, Lejoyeux M, Hindmarch I (2004b). Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: a randomized, double-blind, placebo-controlled discontinuation study. International Clinical Psychopharmacology 19, 271-80.
19. Oehrberg S, Christiansen PE, Behnke K, Borup AL, Severin B, Soegaard J, Calberg H, Judge R, Ohrstrohm JK, Manniche PM (1995). Paroxetine in the treatment of panic disorder. A randomized, double-blind, placebo-controlled study. British Journal of Psychiatry 167, 374-379.
20. Rosenbaum JF, Fava M, Hoog SL, Ascroft RC, Krebs WB (1998). Selective serotonin reuptake inhibitor discontinuation syndrome: A randomized clinical trial. Biological Psychiatry 44, 77-87.
21. Sánchez C, Bøgesø KP, Ebert B, Reines EH, Braestrup C (2004). Escitalopram versus citalopram: the surprising role of the R-enantiomer. Psychopharmacology 174, 163-176.
22. Schatzberg AF, Haddad P, Kaplan EM, Lejoyeux M, Rosenbaum JF, Young AH, Zajecka J (1997). Serotonin reuptake inhibitor discontinuation syndrome: a hypothetical definition. Journal of Clinical Psychiatry 58 (Suppl. 7), 5-10.
23. Stórustovu S, Sánchez C, Pörzgen P, Brennum LT, Larsen AK, Pulis M, Ebert B (2004). R-citalopram functionally antagonizes escitalopram in vivo and in vitro: evidence for kinetic interaction at the serotonin transporter. British Journal of Pharmacology 142, 172-180.
24. Therrien F, Markowitz JS (1997). Selective serotonin reuptake inhibitors and withdrawal symptoms: a review of the literature. Human Psychopharmacology 12, 309-323.